Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2004-06-10
2008-11-18
Gupta, Anish (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C514S012200, C530S308000
Reexamination Certificate
active
07452966
ABSTRACT:
The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
REFERENCES:
patent: WO 02/46227 (2002-06-01), None
STN registry entry, 923950-08-7, Mar. 1, 2007, 2 pages.
Issacs et al. “A Therapeutic Human IgG4 Monoclonal Antibody That Depletes Target Cells In Humans.” Clin. Exp. Immunology, vol. 106, pp. 427-433, 1996.
Glaesner Wolfgang
Millican, Jr. Rohn Lee
Vick Andrew Mark
Cox Gregory A.
Eli Lilly and Company
Gupta Anish
Niebauer Ronald T
LandOfFree
GLP-1 analog fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with GLP-1 analog fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GLP-1 analog fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034430